Jazz Inks Insurer Class Deal As Xyrem Antitrust Trial Nears

By Bonnie Eslinger · March 17, 2025, 8:48 PM EDT

Jazz Pharmaceuticals and a certified insurer class told a California federal judge Monday that they have reached a settlement-in-principle in antitrust litigation accusing Jazz of working with pharma rival Hikma to...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Case Information

Case Title

In re Xyrem (Sodium Oxybate) Antitrust Litigation

Case Number

Court

California Northern

Nature of Suit

Anti-Trust

Date Filed

December 16, 2020

Recent Articles By Bonnie

February 18, 2025
Reed Smith Removed In $102M Shipping Group Award Fight
January 06, 2025
Terraform Victims May Exceed 1M, Feds Say In Notice Request
January 06, 2025
Girard Sharp Launches Into New Year With New Leadership
September 23, 2024
Cargo Airliner ESOP Participants Seek OK On $14.5M Deal
July 29, 2024
Amex Inks $3M Deal To Settle Girardi Bankruptcy Suit Claims
June 25, 2024
2 Federal Judges Stall Biden's Student Loan Debt Relief
April 25, 2024
McDermott Judge U-Turns, Says Some Investors Deserve Cert.
January 24, 2024
PG&E Judge Voices 'Frustration' At Atty Arguing Counsel Bid
December 22, 2023
Bankman-Fried Inks Pact With FTX Debtors Over Embed Deal
December 21, 2023
HSBC Urges Court To Ax First Citizens' $1B SVB Secrets Suit